Physician profile
James K Smith
NPI 1477908846
$2,593.77
in general payments reported to CMS, 2019-2025
14 companies · $46.05 in 2025
The $46.05 reported for 2025 was less than what a typical Podiatrist provider received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $59.94 · 2021: $31.26 · 2022: $80.86 · 2023: $1,756 · 2024: $620 · 2025: $46.05.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,274 · Food and Beverage: $1,148.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,273.74 |
| Food and Beverage | $1,147.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Convatec INC. | $1,415.64 | 2023-2024 | |
| Arthrex, INC. | $278.08 | 2023 | |
| Nevro Corp. | $187.36 | 2022-2024 | Senza |
| Next Science LLC | $169.43 | 2023-2024 | Blastx, Surgx, Xperience |
| Zimmer Biomet Holdings, INC. | $148.23 | 2024 | Tapestry |
| Tricoast Surgical Solutions LLC | $112.17 | 2023 | |
| Organogenesis INC. | $70.92 | 2021-2022 | |
| Smith+Nephew, INC. | $55.67 | 2023 | Renasys Go V2 Home, Grafix Pl, Stravix |
| Medartis INC. | $43.08 | 2019 | |
| Kerecis Limited | $43.08 | 2023-2025 | Kerecis Surgiclose, Kerecis Graftguide, Kerecis Omega3 Surgiclose |
| Averitas Pharma INC. | $25.91 | 2023 | Qutenza |
| Abbott Laboratories | $16.86 | 2019 | |
| Medtronic, INC. | $13.84 | 2022 | |
| Mimedx Group, INC. | $13.50 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.